210344-92-6

Z-VDVAD-FMK is a special inhibitor of caspase-2. Z-VDVAD-FMK produces a reduction in Lovastatin-induced apoptosis[1][2][3].

Irreversible caspase-2 inhibitor. Attenuates oxyhemoglobin-induced cleavage of PARP and apoptosis in endothelial cells.

A cell-permeable inhibitor of caspase-2, which exhibits competitive and irreversible inhibition.

Caspase-2

1. j. d. robertson, m. enoksson et al. caspase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis. the journal of biological chemistry. 277, :29803–29809, 2002 2. t. meguro, b. chen et al. caspase inhibitors attenuate oxyhemoglobin-induced apoptosis in endothelial cells, stroke. 2001; 32:561-566. 3. talanian, r. v., quinlan, c., trautz, s., hackett, m. c., mankovich, j. a., banach, d., ghayur, t., brady, k. d., and wong, w. w. (1997). substrate speci?city of caspase family proteases. j. biol. chem. 272, 9677–9682. 4. gamen et al (2000) doxorubicin treatment activates a z-vad-sensitive caspase, which causes dym loss, caspase-9 activity, and apoptosis in jurkat cells. exp.cell res. 258 223.